Cardiovascular Changes in Infants of Preeclampsia Mother

Status Not yet recruiting

Clinical Trial Summary

Preeclampsia (hypertension during pregnancy) is a common problem affecting 2-8% of pregnancies worldwide and is typically diagnosed by increased blood pressure and proteinuria. The rate of preeclampsia has increased since the 1980s with higher rates at extreme maternal ages as well as during the first pregnancy. Pre-eclampsia is a serious hypertensive disorder of pregnancy affecting outcomes for both mother and infants. These infants not only have increased risk of neonatal complications including preterm birth, intrauterine growth restriction, abnormal Doppler parameters, feed intolerance, intestinal problem, poor growth, and long term lung condition but also have increased risk of cerebral palsy, abnormal neurodevelopmental outcomes, cardiovascular disease, stroke, and mental disorders during childhood and adulthood.

Clinical Trial Description

Preeclampsia is diagnosed according to the International Society for the Study of Hypertension in Pregnancy (ISSHP) criteria: BP > 140/90 on two occasions in previous normotensive mother after 20 weeks of gestation and one of the following; proteinuria in urine > 0.3 gram/kg/day or acute kidney or liver dysfunction or signs of uterine dysfunction. The onset of preeclampsia can be early before 34 weeks of pregnancy (Early-onset preeclampsia) or late after 34 weeks of pregnancy (Late-onset preeclampsia). Early-onset preeclampsia, especially between 28-32 weeks gestation, is characterized by a high prevalence of microvascular changes in the placenta that makes mothers and their infants are more liable to complication. The pathogenesis of preeclampsia is unclear. Preeclampsia affects hematopoiesis and the fetal myeloid lineage leading to thrombocytopenia, neutropenia, decrease phagocytic function, decrease T regulatory cells, and an increase in cytotoxic natural killer cells in neonates. Innate and adaptive immunity are regulated by myeloid cells and the immune changes in infants of preeclampsia mothers could lead to increased incidence of neonatal sepsis and the development of chronic inflammatory conditions. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04699825
Study type	Interventional
Source	Assiut University
Contact	Ahmed S Ali
Phone	7309405405
Email	ahmedsalehali@aun.edu.eg
Status	Not yet recruiting
Phase	N/A
Start date	April 1, 2021
Completion date	October 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03299777` - Correlation Between Changes in Liver Stiffness and Preeclampsia as Shown by Fibroscan	N/A
Completed	`NCT03650790` - C1q/TNF-related Protein 9 (CTRP 9) Level in Preeclamptic Obese and Non-obese Pregnancies	N/A
Recruiting	`NCT03605511` - TTP and aHUS in Complicated Pregnancies
Not yet recruiting	`NCT03302260` - Identifying Methods for Postpartum Reduction of Vascular Events: Pilot Randomized Controlled Trial	N/A
Completed	`NCT02911701` - Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features	Phase 4
Completed	`NCT01911494` - Community Level Interventions for Pre-eclampsia	N/A
Terminated	`NCT02025426` - Phenylephrine Versus Ephedrine in Pre-eclampsia	Phase 4
Completed	`NCT01352234` - Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia	Phase 4
Active, not recruiting	`NCT02031393` - Establishing First Trimester Markers for the Identification of High Risk Twin	N/A
Terminated	`NCT00141310` - Sildenafil Citrate for the Treatment of Established Pre-Eclampsia	Phase 2
Completed	`NCT00157521` - L-Arginine in Pre-Eclampsia	Phase 3
Completed	`NCT04795154` - Prenatal Yoga as Complementary Therapy of Preeclampsia	N/A
Completed	`NCT00004399` - Randomized Study of Nimodipine Versus Magnesium Sulfate in the Prevention of Eclamptic Seizures in Patients With Severe Preeclampsia	N/A
Completed	`NCT00005207` - Renin and Prorenin in Pregnancy	N/A
Recruiting	`NCT04551807` - Natural Versus Programmed Frozen Embryo Transfer (NatPro)	Phase 3
Terminated	`NCT04092829` - Impact of Corpus Luteum Presence or Absence in the Incidence of Preeclampsia After Frozen Embryo Transfer	N/A
Recruiting	`NCT06067906` - Weight Loss Following an Episode of Pre-eclampsia Using a Dissociated or Hypocaloric Diet in Overweight or Obese Patients	N/A
Recruiting	`NCT06317467` - Role of Anti-C1q Autoantibodies in Pregnancy
Completed	`NCT02218931` - ESTEEM - Effect of Simple, Targeted Diet in Pregnant Women With Metabolic Risk Factors on Pregnancy Outcomes	N/A
Active, not recruiting	`NCT04484766` - Preeclampsia Associated Vascular Aging

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.